Exchange: NASDAQ·Updated 07:54 PM EDT
ENTX logo

ENTXEntera Bio Ltd

$1.66
$0.03
(1.77%)
Today
Closed $1.66
$0.0148
(0.89%)
After Hours
Mkt Cap$83.3M
Vol126,635.00
News
all
press releases
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus
DELL, CAT and AMKR led standout gains as Zacks highlighted top-performing portfolios amid volatile markets and inflation worries.
Zacks
News Placeholder
More News
News Placeholder
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.
Stocktwits
News Placeholder
Entera Bio (ENTX) to Release Earnings on Friday
Entera Bio (NASDAQ:ENTX) will be releasing its Q1 2026 earnings after the market closes on Friday, May 8. (View Earnings Report at...
MarketBeat
News Placeholder
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
What is HC Wainwright's Estimate for Entera Bio Q1 Earnings?
Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, April 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0...
MarketBeat
News Placeholder
HC Wainwright Has Lowered Expectations for Entera Bio (NASDAQ:ENTX) Stock Price
HC Wainwright lowered their price objective on shares of Entera Bio from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...
MarketBeat
News Placeholder
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near
Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as persistent gaps in osteoporosis care and the potential role for the...
MarketBeat
News Placeholder
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update
Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 175,306 shares, a growth of 27.2% from the March 15th total of 137,789 shares. Currently, 0.4% of the shares of the...
MarketBeat
News Placeholder
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners...
PR Newswire
News Placeholder
Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'Palantir, Rezolve AI, Entera Bio In Focus
U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% below their 52-week highs.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.